NVS Jan 2024 70.000 put
| Previous close | 1.5000 |
| Open | 1.5000 |
| Bid | 0.6000 |
| Ask | 4.6000 |
| Strike | 70.00 |
| Expiry date | 2024-01-19 |
| Day's range | 1.5000 - 1.6000 |
| Contract range | N/A |
| Volume | |
| Open interest | 140 |
- GlobeNewswire
Patients with hidradenitis suppurativa experienced sustained efficacy and symptom improvement at one year when treated with Novartis Cosentyx®
In two of the largest Phase III trials conducted in hidradenitis suppurativa (HS), Cosentyx® (secukinumab) treatment response rates continued to improve beyond the primary endpoint analysis at Week 16 to more than 55% at Week 52, as evaluated by the HS Clinical Response (HiSCR) measure1 Safety findings were consistent with the well-established safety profile of Cosentyx in its approved indications1 HS is a recurrent skin disease affecting one in 100 people worldwide, causing painful, boil-like a
- Simply Wall St.
Novartis Full Year 2022 Earnings: Misses Expectations
Novartis ( VTX:NOVN ) Full Year 2022 Results Key Financial Results Revenue: US$51.8b (down 2.0% from FY 2021). Net...
- Zacks
Novartis (NVS) Q4 Earnings Top, Revenues Miss Estimates
Novartis (NVS) reports mixed fourth-quarter results, with key brands maintaining momentum but Cosentyx sales declining and generic competition remaining a drag.
